These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11026044)

  • 21. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family.
    Nordling M; Karlsson P; Wahlström J; Engwall Y; Wallgren A; Martinsson T
    Cancer Res; 1998 Apr; 58(7):1372-5. PubMed ID: 9537232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Brca1 and Brca2 proteins and tumor pathogenesis.
    Ingvarsson S
    Anticancer Res; 1999; 19(4B):2853-61. PubMed ID: 10652564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA2 germline mutations in Swedish breast cancer families.
    Chen J; Hedman MZ; Arver BW; Sigurdsson S; Eyfjörd JE; Lindblom A
    Eur J Hum Genet; 1998; 6(2):134-9. PubMed ID: 9781057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
    Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N
    Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
    Phillips KA
    J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pregnancy and risk of early breast cancer in patients sith BRCA1 and BRCA2 mutations].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2000 Jul; 176(7):335-6. PubMed ID: 10963002
    [No Abstract]   [Full Text] [Related]  

  • 29. Laboratory identification of hereditary risk of breast and ovarian cancer.
    Frank TS
    Curr Opin Biotechnol; 1999 Jun; 10(3):289-94. PubMed ID: 10361081
    [No Abstract]   [Full Text] [Related]  

  • 30. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
    Chen-Shtoyerman R; Figer A; Fidder HH; Rath P; Yeremin L; Bar Meir S; Friedman E; Theodor L
    Br J Cancer; 2001 Feb; 84(4):475-7. PubMed ID: 11207040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
    FitzGerald MG; MacDonald DJ; Krainer M; Hoover I; O'Neil E; Unsal H; Silva-Arrieto S; Finkelstein DM; Beer-Romero P; Englert C; Sgroi DC; Smith BL; Younger JW; Garber JE; Duda RB; Mayzel KA; Isselbacher KJ; Friend SH; Haber DA
    N Engl J Med; 1996 Jan; 334(3):143-9. PubMed ID: 8531968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer.
    Barnes DM
    Histopathology; 1999 Feb; 34(2):170-4. PubMed ID: 10064397
    [No Abstract]   [Full Text] [Related]  

  • 35. Insights into the functions of BRCA1 and BRCA2.
    Welcsh PL; Owens KN; King MC
    Trends Genet; 2000 Feb; 16(2):69-74. PubMed ID: 10652533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity?
    Formenti SC; Preston-Martin S; Haffty BG
    J Clin Oncol; 2000 Mar; 18(5):1159-60. PubMed ID: 10694571
    [No Abstract]   [Full Text] [Related]  

  • 37. [Male breast cancer].
    Shin E
    Nihon Rinsho; 2000 Apr; 58 Suppl():571-4. PubMed ID: 11026052
    [No Abstract]   [Full Text] [Related]  

  • 38. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.
    Brugarolas J; Jacks T
    Nat Med; 1997 Jul; 3(7):721-2. PubMed ID: 9212093
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition.
    Scully R
    Breast Cancer Res; 2000; 2(5):324-30. PubMed ID: 11250724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2.
    Liede A; Rehal P; Vesprini D; Jack E; Abrahamson J; Narod SA
    Am J Hum Genet; 1998 Jun; 62(6):1543-4. PubMed ID: 9585617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.